Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Nab-paclitaxel in Melanoma
NCT02300935Phase 1Withdrawn
- Sponsor
- SCRI Development Innovations
- Start
- Dec 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trametinib and paclitaxel in melanoma, sponsored by SCRI Development Innovations. Primary endpoint: Number of patients with Adverse Events at 4 weeks. Planned start Dec 2015; status: withdrawn.
02
Drugs
trametinibpaclitaxel
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02300935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02300935.